Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions

Manja Wobus, Robin Kuns, Irene Sheyn, Bruce A. Werness, Nader Husseinzadeh, Bernard S. Aron, Larry S. Sherman

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The erbB2 receptor tyrosine kinase and the CD44 transmembrane glycoprotein interact with one another in numerous cell types. This interaction helps to maintain erbB2 activity that contributes to tumor progression. We investigated whether CD44 and erbB2 similarly interact in endometrial carcinomas in vitro and in situ. In contrast to other carcinomas, CD44 did not colocalize with erbB2 in any of the 51 cases of endometrial cancer analyzed. CD44 also did not coimmunoprecipitate or colocalize with erbB2 in two endometrial carcinoma cell lines. We propose that the lack of CD44-erbB2 interactions may reduce the contribution of erbB2 to endometrial carcinoma progression.

Original languageEnglish (US)
Pages (from-to)242-246
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Issue number3
StatePublished - Sep 1 2002
Externally publishedYes


  • CD44
  • Endometrial carcinoma
  • erbB2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology


Dive into the research topics of 'Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions'. Together they form a unique fingerprint.

Cite this